alexa Advantages of Jelly over Liquid Formulations for Pediatrics | OMICS International
ISSN: 2577-0543
Journal of Formulation Science & Bioavailability
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Advantages of Jelly over Liquid Formulations for Pediatrics

Doolaanea AA* and Bahari AZBS

Advanced Drug Delivery Lab, Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia, 25200 Kuantan, Malaysia

*Corresponding Author:
Doolaanea AA
Advanced Drug Delivery Lab
Department of Pharmaceutical Technology
Kulliyyah of Pharmacy
International Islamic University, Malaysia
Tel: +60136238628
E-mail: [email protected]

Received Date: January 04, 2017; Accepted Date: January 24, 2017; Published Date: February 06, 2017

Citation: Doolaanea AA, Bahari AZBS (2017) Advantages of Jelly over Liquid Formulations for Pediatrics. J Formul Sci Bioavailab 1: 102.

Copyright: © 2017 Doolaanea AA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Formulation Science & Bioavailability


Jellies for oral administration are non-flowable gelatinous preparations having a certain shape and size. This dosage form is being explored for applications for pediatric patients and other populations like geriatric and dysphagic patients. It has several advantages over liquid dosage forms in term of palatability, patient acceptance, suitability for controlled release applications and stability. Due to lack of information of several aspects of jellies for pediatrics, much more further studies are encouraged.


Jelly; Pediatric; Formulation; Liquid dosage

Definition of Jellies

According to the Japanese Pharmacopeia 17th edition (JP XVII) [1], jellies for oral administration are non-flowable gelatinous preparations having a certain shape and size, intended for oral administration. The United States Pharmacopoeia does not have jellies for oral administration. Instead, it prefers to use the term ‘gel’ which is not to be ingested [2]. This is the definition in USP: ‘Jelly (not preferred; see Gel): A semisolid dispersion of small particles or a solution of large organic molecules interpenetrated by a solution containing a gelling agent to promote stiffness.’ Jellies are usually prepared by mixing active substance(s) with suitable excipients and polymer gel base, gelatinizing and forming into a certain shape and size by a suitable method [1].

The JP XVII states that jellies for oral administration meet the requirements of dissolution test or show an appropriate disintegration. In addition, jellies for oral administration meet the requirements of ‘Uniformity of Dosage Units’ [1]. This test is usually required for dosage forms that are packaged in single-dose container. For packaging, JP XVII states that tight containers are usually used for jellies for oral administration; for the preparations that are susceptible to degradation by evaporation of water, a low moisture-permeability container or packaging may be used.

Jellies Compared to Liquid Formulations

Pediatric oral formulations can be scientifically challenging to develop. The prerequisites for both a measurable dosage form based upon bodyweight and taste-masking are two of the challenges unique for pediatric oral formulations. The majority of active pharmaceutical ingredients (APIs) found in oral dosage forms have bitter taste [3]. Taste masking of liquid formulation presents a major challenge because most of pediatric preparations are syrups and suspensions. Taste masked drug delivery research is gaining importance and commercial success for the quality of treatment provided to suffering patients, especially children [4].

Pediatric population cover the age from birth up to age 16 or 18.

This population can be subdivided according to the document from European Medicines Agency (EMEA) as following [5]:

• Preterm newborn infants.

• Term newborn infants (0-27 days).

• Infants and toddlers (1 month to 23 months).

• Children (2-11 years): could be further subdivided in terms of the child’s ability to accept and use different dosage forms, e.g. into preschool children (2-5 years) and school children (6-11 years).

• Adolescents (12-16 or 18 years).

The physicochemical and organoleptic properties of the active drug substance such as solubility, chemical stability, and taste along with the intended dose can determine which formulations are feasible to develop. Strickley [6] reported that oral pediatric formulations are available in 17 different varieties and can be either; ready-to-use formulations such as a (1) solution, (2) syrup, (3) suspension, (4) tablet, (5) scored tablet, (6) chewable tablet, (7) orally disintegrating tablet, or (8) thin strip, or formulations that require manipulation such as a (9) powder for constitution to a suspension, (10) tablet for constitution to a suspension, (11) powder for constitution to a solution, (12) drops for reconstitution to a suspension, (13) concentrated solution for dilution, (14) effervescent tablet, (15) bulk oral granules, (16) bulk oral powder, or (17) solid in a capsule to mix with food or drink.

According to our search, no new pediatric dosage form was commercialized other than those reported in the previous study. A careful view on the 17 dosage forms leads to conclude that the final dosage forms that the pediatric will administer (after reconstitution) can be classified into:

a) Liquid dosage forms: solutions, syrup, suspension, powder for constitution to a suspension, tablet for constitution to a suspension, powder for constitution to a solution, drops for reconstitution to a suspension, concentrated solution for dilution, effervescent tablet.

b) Solid dosage forms: tablet, scored tablet, chewable tablet, orally disintegrating tablet, thin strip, bulk oral granules, bulk oral powder and solid in a capsule to mix with food or drink.

A major concern is at what age children can safely swallow solid oral dosage forms such as tablets or capsules. Again, this is generally a factor of age and health status but there are significant inter-patient differences around an average of about 6 years. Taste, smell and texture will be important factors for any medicine administered orally. Children are unlikely to tolerate repeated administration of medicinal products, which are uncomfortable, painful or stressful [5]. It is estimated that 50% of the population have problem of swallowing tablets, especially the pediatric and geriatric population [7].

Current pediatric dosage forms have several drawbacks especially for the age below 6 years. The ideal pediatric formulation needs to consider the following criteria as suggested by European Medicines Agency [5]:

• Minimal dosage frequency,

• One dosage form fits all or a full range,

• Minimal impact on life style,

• Minimum, non-toxic excipients,

• Convenient, easy, reliable administration,

• Easily produced, elegant, stable,

• Cost and commercial viability.

Current liquid dosage forms provide several advantages such as dose flexibility and ease of swallowing. In fact, they are the most appropriate for younger pediatric patients. However, liquid dosage forms have several disadvantages, among them [5].

• The dose volume is a major consideration:

• Less than 5 ml for children under 5 years

• Less than 10 ml for children of 5 years and older,

• Stability issues: the drug is being in solution or suspension form and hence easier for degradation.

• Patient acceptability: since the drug is completely or partially dissolved it will be in direct contact with the taste sensors in the tongue. This introduces challenges in taste masking and requires high sugar or sweetener concentrations to be used.

• Challenging controlled release: only few sustained release liquid formulations are available in the market.

• Higher transportation costs: due to the large weight of the product.

On the other hand, jellies may address majority of the drawback of the liquid dosage forms. Jellies have higher viscosity than liquid preparations and this property gives jellies advantage in taste masking. Gohel [8] formulated paracetamol in oral jelly (referred as gel in their publication) and found that paracetamol jellies possessed acceptable sensory characteristics when evaluated by human volunteers. Paracetamol is a well-known drug for its very bitter taste. The more palatable the formulation, the higher the dose volume can be tolerated [5]. Therefore, jelly volumes higher than 10 ml might be administered by pediatrics without difficulties.

In addition, controlled release is possible in jelly formulations and it is more practical than liquid formulations. Paracetamol in sustained release jelly formulation was investigated by using carrageenan as gelling agent Miyazaki [9] and other gelling agents like agar, gelatin, gellan, pectin and xyloglucan [10]. In these studies, the sustained release property was achieved through the vehicle itself. By choosing the right gelling agent at suitable concentration, the drug released slowly from the jelly vehicle.

On the other hand, like suspension dosage forms; jellies may be used to suspend drug particle, drug microparticles or pellets. In this case, the sustained release properties may result from the particles themselves and the jelly will serve as a vehicle that carries the particles. In this proposed formulation, the jelly formulation may have advantages over the suspension. The high viscosity of the jellies prohibits the suspended particles from sedimentation.

In term of drug stability, there is lack of information regarding stability of drugs in jelly vehicle or the relation between the drug degradation and viscosity of the vehicle. However, from the concept of chemical reactions, it can be predicted that molecules move slower at higher viscosity leading to slower reaction and so on slower degradation than liquid solutions. More experimental data are needed to verify this anticipation.


Jelly as an oral dosage form for pediatrics is being explored. It has high potential due to several advantages over liquid formulations in term of patient acceptance, suitability for controlled release applications, stability and other aspects. More studies are needed to further explore this new dosage form.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Journals

Article Usage

  • Total views: 1080
  • [From(publication date):
    November-2017 - Jun 23, 2018]
  • Breakdown by view type
  • HTML page views : 974
  • PDF downloads : 106

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7